Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study

Author
Richarz, U.
Fizazi, K.
Leitz, G.
Hu, P.
Chi, K. N.
Baciarello, G.
ÖZGÜROĞLU, Mustafa
Mundle, S. D.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/3580
https://doi.org/10.1016/j.annonc.2020.08.910
Collections